We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $610M
1-Year Est. Return 40.86%
This Fund
S&P 500
This Quarter Est. Return
+22.79%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$359M
AUM Growth
+$110M
Cap. Flow
+$97.8M
Cap. Flow %
27.21%
Top 10 Hldgs %
61.96%
Holding
53
New
19
Increased
12
Reduced
12
Closed
9

Top Buys

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$20.1M
2
BBIO icon
BridgeBio Pharma
BBIO
+$20M
3
CYTK icon
Cytokinetics
CYTK
+$18.9M
4
GH icon
Guardant Health
GH
+$10.1M
5
KIDS icon
OrthoPediatrics
KIDS
+$9.04M

Top Sells

Rank Stock Value
1
ORIC icon
Oric Pharmaceuticals
ORIC
+$14.5M
2
QDEL icon
QuidelOrtho
QDEL
+$8.76M
3
PCRX icon
Pacira BioSciences
PCRX
+$5.04M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$4.68M
5
NUVB icon
Nuvation Bio
NUVB
+$3.46M

Sector Composition

Rank Sector Weight
1 Healthcare 96.72%
2 Industrials 3.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRE icon
51
Spyre Therapeutics
SYRE
$8.87B
– –
-55,000
Closed -$1.18M
SWAV
52
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
– –
-5,000
Closed -$953K
MDRX
53
DELISTED
Veradigm Inc. Common Stock
MDRX
– –
-180,000
Closed -$1.89M
1 2
3

Similar funds

PL
Pandi LLC Leawood, Kansas $610M AUM 14.97% 1-Year Est. Return
BFC
Blue Fin Capital Warren, Rhode Island $610M AUM 26.46% 1-Year Est. Return
DCM
DGS Capital Management Jersey City, New Jersey $609M AUM 44.78% 1-Year Est. Return
SAM
Strategy Asset Managers Pasadena, California $609M AUM 32.56% 1-Year Est. Return
CBB
Citizens Business Bank Ontario, California $610M AUM 27.86% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
FFWA
FRG Family Wealth Advisors Bellevue, Washington $611M AUM 25.92% 1-Year Est. Return
CIP
Convergence Investment Partners Palm Beach Gardens, Florida $611M AUM 61.48% 1-Year Est. Return

Prosight Management's Q1 2024 Portfolio in Review

As of Q1 2024, Prosight Management held 53 positions worth $359M, up 44% from $249M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Prosight Management deployed $97.8M of net new capital in Q1 2024, opening 19 new positions and adding to 12 existing holdings. Its largest new stake was Roivant Sciences: 1,860,000 shares worth $19.6M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Pacira BioSciences, an estimated $5.04M trimmed.

  • Prosight Management's largest Q1 2024 buy was Roivant Sciences: 1,860,000 shares worth $19.6M.
  • Prosight Management added most to OrthoPediatrics in Q1 2024, an estimated $9.04M increase.
  • Prosight Management's biggest Q1 2024 reduction was Pacira BioSciences, cutting an estimated $5.04M.
  • Prosight Management fully exited Oric Pharmaceuticals in Q1 2024, selling an estimated $14.5M.
  • Prosight Management's ten largest holdings make up 62% of its $359M portfolio in Q1 2024.
  • Prosight Management opened 19 new positions and closed 9 in Q1 2024.
  • Prosight Management's portfolio value rose 44% quarter-over-quarter to $359M.

Based on Prosight Management's 13F filing for Q1 2024, filed 15 May 2024.